X0306 4 2021-06-10 0 0001029142 DYNAVAX TECHNOLOGIES CORP DVAX 0001657434 Hack Andrew A. F. C/O BAIN CAPITAL LIFE SCIENCES INVESTORS 200 CLARENDON STREET BOSTON MA 02116 1 0 0 0 Common Stock 8525000 I See footnotes Warrants (Right to Buy) 4.50 2021-06-10 4 S 0 2916250 D 2019-08-12 2022-02-12 Common Stock 2916250 0 I See footnotes Series B Convertible Preferred Stock 0.00 2019-08-12 Common Stock 4140000 4140000 I See footnotes Represents securities held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"). Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. On June 10, 2021, the Bain Capital Life Sciences Entities sold warrants to purchase an aggregate of 2,916,250 shares of common stock of the Issuer for aggregate consideration of $11,839,914. Each share of Series B Convertible Preferred Stock is convertible, at the option of the holder, into 1,000 shares of the Issuer's common stock and has no expiration date. The Series B Convertible Preferred Stock is not convertible if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then issued and outstanding immediately after giving effect to the conversion. /s/ Andrew Hack 2021-06-11